JAK2 (phospho Tyr1007/1008) antibody
GTX132784
ApplicationsWestern Blot
Product group Antibodies
TargetJAK2
Overview
- SupplierGeneTex
- Product NameJAK2 (phospho Tyr1007/1008) antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.25 mg/ml
- ConjugateUnconjugated
- Gene ID3717
- Target nameJAK2
- Target descriptionJanus kinase 2
- Target synonymsJTK10, tyrosine-protein kinase JAK2, JAK-2, Janus kinase 2 (a protein tyrosine kinase)
- HostRabbit
- IsotypeIgG
- Protein IDO60674
- Protein NameTyrosine-protein kinase JAK2
- Scientific DescriptionThis gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Li CJ, Tsai HW, Chen YL, et al. Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2023,10:123-138. doi: 10.2147/JHC.S385238Read this paper
- Lin ZH, Hu J, Shi H, et al. Water extract of medicinal ink (WEMI) attenuates lipopolysaccharide-induced NO production of Raw264.7 cells via downregulating JAK2/STAT3-mediated iNOS expression. J Ethnopharmacol. 2022,282:114636. doi: 10.1016/j.jep.2021.114636Read this paper
- Shen M, Xu Z, Xu W, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. 2019,38(1):149. doi: 10.1186/s13046-019-1161-8Read this paper





